SecBot SecBot

GMAB drug pipeline

GENMAB A/S · 1 rated drug
$51.57
+0.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±4.2%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketRegulatory submission discussions are underway following positive Phase 3 data. If filed in 2026-2027, potential FDA approval could come in 2027-2028, though the timeline depends on regulatory interactions and whether accelerated pathways are pursued.

rinatabart sesutecan Updated Oct 23

What to watch

The Phase 3 RAINFOL-02 readout (Oct 23, 2026) was a major derisking event for Rina-S with highly compelling efficacy data. Watch the October 28 investor update for regulatory filing timelines and commercial opportunity sizing. The stock is near its 52-week high with strong technical momentum but RSI overbought at 78, near-term pullback risk exists after the recent run-up.

Bull case
  • Phase 3 RAINFOL-02 results were exceptionally strong: 71% reduction in risk of progression/death (PFS HR 0.29, p<0.0001) and 57% reduction in risk of death (OS HR 0.43, p<0.0001) in ITT population, best-in-class potential versus existing therapies
  • Rina-S is wholly owned by Genmab, meaning 100% of commercial upside accrues to shareholders if approved
  • Five ongoing Phase 3 trials across multiple gynecologic cancers (endometrial, first-line ovarian, PSOC maintenance) provide significant label expansion optionality beyond PROC
Bear case
  • Competition from already-approved FRα-targeted ADC mirvetuximab soravtansine (Elahere) in platinum-resistant ovarian cancer, which may have a first-mover advantage
  • Regulatory approval is not guaranteed despite positive data; FDA could request additional trials or impose label restrictions
  • Manufacturing scale-up and commercial launch execution risks for a wholly-owned Genmab asset (company has limited commercial experience with wholly-owned products)

Other drugs in filings and trials

no drug report yet
  • EPKINLY Last: Approval · May 19, 2023
  • GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. 1 trial
  • GEN1107 1 trial
  • GEN1286 1 trial

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
May 19, 2023EPKINLYApproval+4.2%−0.1%

Clinical trials

9 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
EpcoritamabSubcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaPhase 2Terminated111Jun 10, 2026
AcasunlimabStudy of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)Phase 2Terminated · results1May 15, 2026
GEN1286A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid TumorsPhase 2Terminated23Mar 30, 2026
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.GEN1047 for Solid Tumors - First in Human (FIH) TrialPhase 2Terminated179Mar 25, 2026
GEN1055Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination TherapyPhase 2Terminated · results21Nov 20, 2025
GEN1107PRO1107 in Patients With Advanced Solid TumorsPhase 2Terminated · results33Aug 18, 2025
GEN1042A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid TumorsPhase 2Terminated · results13Aug 11, 2025
AcasunlimabGEN1046 Safety Trial in Patients With Malignant Solid TumorsPhase 2Terminated · results429Apr 1, 2025
AcasunlimabSafety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerPhase 2Terminated125Dec 2, 2024